Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Rhabdomyosarcoma 5Wilms Tumor 4Sarcoma 4Hydatidiform Mole 2Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdoid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Melanoma 1Malignant mesenchymal tumor 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Fibrosarcoma 1Choroid Plexus Neoplasms 1Choriocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Brain Neoplasms 1Blast Crisis 1Beckwith-Wiedemann Syndrome 1

Interventions

temsirolimus 1ganitumab 1efineptakin alfa 1Vinorelbine 1Vincristine 1Sirolimus 1Receptor Protein-Tyrosine Kinases 1Radiotherapy 1Radiation 1Irinotecan 1Dasatinib 1Dactinomycin 1Cyclophosphamide 1BAY 1895344 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Rhabdomyosarcoma, Alveolar × Dactinomycin × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡